Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986446 in healthy Chinese participants
NCT07852962Phase 1Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2027
- Primary completion
- Jul 2027
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing BMS-986446 with Placebo (2 arms). Primary endpoints: Maximum observed plasma concentration, Time of maximum observed plasma concentration and 5 more. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
PRX005
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07852962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07852962.